Logo

Insmed's Brensocatib Receives the US FDA's Breakthrough Therapy Designation to Treat Non-Cystic Fibrosis Bronchiectasis

Share this
Insmed's Brensocatib Receives the US FDA's Breakthrough Therapy Designation to Treat Non-Cystic Fibrosis Bronchiectasis

Insmed's Brensocatib Receives the US FDA's Breakthrough Therapy Designation to Treat Non-Cystic Fibrosis Bronchiectasis

Shots:

  • The BTD is based on P-II WILLOW study assessing brensocatib vs PBO in adults with NCFBE for reducing exacerbations
  • Insmed expects to initiate a P-III program for brensocatib in bronchiectasis in the H2’21
  • Brensocatib is a novel oral- reversible DPP1 inhibitor- currently being developed for the treatment of bronchiectasis and other inflammatory diseases

 ­ Ref: PRNewswire | Image: Twitter

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions